Back to results
US 2012/0252773 A1Published application
Method and composition for inhibiting cell proliferation and angiogenesis
OwnerKhalid Amin, Joy M. Calaoagan +5inventors
InventorsKhalid Amin, Joy M. Calaoagan, Wan-Ru Chao, Peter D. Hobbs, Keith R. Laderoute, Richard H. Peters, Masato Tanabe
Life of this patent
Estimating the term…
Abstract
A method is provided for treating a patient with a medical condition that involves angiogenesis or HIF-1 overexpression with a compound having the structure of formula (I) wherein Z, x, y, and R1 through R11 are as defined herein.
Claims21
1-20. (canceled)
A method for inhibiting HIF-1α comprising:
- (a) contacting cells with a compound of formula (I) sufficient to inhibit HIF-1α in the cells, wherein formula (I) is:
- wherein:
- Z is —O-(L)q-, —S-(L)q-, or —NR12-(L)q- wherein q is zero or 1, L is monocyclic aryl optionally substituted with up to 4 substituents independently selected from hydrogen, hydroxyl, C1-C6 alkoxy, C1-C6 alkyl, halo, amino, and C1-C6 alkyl-substituted amino, wherein any two adjacent substituents on L may be taken together to form an optionally substituted cyclic structure, and R12 is hydrogen or C1-C6 alkyl;
- x is an integer in the range of 1 to about 6 inclusive;
- when q is zero, y is an integer in the range of 2 to about 6 inclusive, and when q is 1, y is an integer in the range of 1 to about 6 inclusive;
- R1 and R2 are independently selected from hydrogen and C1-C6 alkyl, or can be taken together to form an optionally substituted nitrogen heterocycle containing zero to two additional heteroatoms;
- R3 is selected from hydrogen, hydroxyl, C1-C6 alkoxy, halo, C1-C3 alkyl, C2-C3 alkenyl, monocyclic aryl, and monocyclic aryl-substituted C1-C3 alkyl;
- R4 is hydrogen or C1-C6 alkyl;
- R5 is selected from hydrogen, C1-C6 alkoxy, halo, cyano, C1-C6 alkyl, and C2-C6 alkenyl;
- R6 is selected from hydrogen, C1-C6 alkyl, C2-C12 acyl, and —SO2NH2;
- R7 is selected from hydrogen, halo, C1-C6 alkyl, C2-C6 alkenyl, —OR13 and —SR13 where R13 is C1-C6 alkyl, C2-C6 acyl, or aryl;
- R8 is hydrogen, C1-C6 alkoxy, or hydroxyl;
- R9 is selected from hydrogen, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, aryl, and alkaryl;
- and
- R10 and R11 are independently selected from hydrogen, C1-C6 alkoxy, and C1-C6 alkyl,
- or a pharmaceutically acceptable salt thereof;
- and
- wherein (i) the method further comprises the step of detecting in the cells HIF-1α expression, or (ii) the contacting step comprises administering a therapeutically effective amount of the compound to a patient comprising the cells wherein the patient is diagnosed with having an ocular disorder associated with ocular neovascularization or a chronic inflammatory condition.
15 more elements
Dependencies are inferred from the claim text.